BPG is committed to discovery and dissemination of knowledge
Review
©The Author(s) 2026.
World J Gastroenterol. Jan 7, 2026; 32(1): 112496
Published online Jan 7, 2026. doi: 10.3748/wjg.v32.i1.112496
Table 18 Messenger RNA therapy in disorders of gastrointestinal tract
Agent/platform
Target/indication (GIT)
Study type/phase
RNA-4157/V940 (Moderna)Individualized neoantigen vaccine colorectal cancerPhase 2b/3 trial undergoing
BioNTech iNeST/BNT-pipeline Personalized or fixed mRNA cancer vaccines for CRC, pancreatic, HCCPhase 1/2 trials
Gritstone GRANITEPersonalized neoantigen immunotherapy MSS colorectal cancerPhase 2 trial
MSK/investigator-initiated mRNA vaccinePersonalized mRNA neoantigen vaccine pancreatic adenocarcinomaEarly phase trial
OX40 L mRNA (LNP delivery)Immune costimulatory agonist mRNA for HCCPreclinical


Write to the Help Desk